Mirae Asset Global Etfs Holdings Ltd. C4 Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 33,675 shares of CCCC stock, worth $72,738. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,675
Previous 37,837
11.0%
Holding current value
$72,738
Previous $215,000
43.72%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CCCC
# of Institutions
126Shares Held
63MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$15.1 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$14.8 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$13.1 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$10.5 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$9.83 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $106M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...